Abstract
Cancer constitutes a key pressure on public health regardless of the economy state in different countries. As a kind of highly malignant epithelial tumor, lacrimal gland adenoid cystic carcinoma can occur in any part of the body, such as salivary gland, submandibular gland, trachea, lung, breast, skin and lacrimal gland. Chemotherapy is one of the key treatment techniques, but drug resistance, especially MDR, seriously blunts its effects. As an element of the 60S large ribosomal subunit, the ribosomal protein L39-L gene appears to be documented specifically in the human testis and many human cancer samples of different origins. Total RNA of cultured drug-resistant and susceptible lacrimal gland adenoid cystic carcinoma cells was seperated, and real time quantitative RT-PCR were used to reveal transcription differences between amycin resistant and susceptible strains of lacrimal gland adenoid cystic carcinoma cells. Viability assays were used to present the amycin resistance difference in a RPL39-L transfected lacrimal gland adenoid cystic carcinoma cell line as compared to control vector and null-transfected lacrimal gland adenoid cystic carcinoma cell lines. The ribosomal protein L39-L transcription level was 6.5-fold higher in the drug-resistant human lacrimal gland adenoid cystic carcinoma cell line than in the susceptible cell line by quantitative RT-PCR analysis. The ribosomal protein L39-L transfected cells revealed enhanced drug resistance compared to plasmid vector-transfected or null-transfected cells as determined by methyl tritiated thymidine (3H-TdR) incorporation. The ribosomal protein L39-L gene could possibly have influence on the drug resistance mechanism of lacrimal gland adenoid cystic carcinoma cells.
Highlights
The international agency for research on cancer (IARC) reported that tumor had threatened the public’s health in countires all over the world, whether rich or poor (McCormack et al, 2012). 7.6 million people were died of cancer in 2008, and the number were estimated to rise to 11 millions in the year of 2030 according to the present progress pattern (Bray et al, 2012)
T-test: n =3, p= 0.04.null-cell: nothing transfected in adenoid cystic carcinoma (ACC) cell line; vector: ACC cell line transfected with vector; RPL39-L: ACC cell line transfected with RPL39-L
The results suggested that RPL39-L expression was up-regulated in drug-resistant human adenoid cystic carcinoma cell line (Figure 1)
Summary
The international agency for research on cancer (IARC) reported that tumor had threatened the public’s health in countires all over the world, whether rich or poor (McCormack et al, 2012). 7.6 million people were died of cancer in 2008, and the number were estimated to rise to 11 millions in the year of 2030 according to the present progress pattern (Bray et al, 2012). Chemotherapy is one of the key treatment techniques, but drug resistant, especially MDR, had seriously affected its effect. Earlier experiments of our research group collected the results to prove that the adenoid cystic carcinoma (ACC) adriamycin resistant strain has a high ribosomal proteins expression level, such as ribosomal. As a kind of highly malignant epithelial tumor, lacrimal gland adenoid cystic carcinoma can occur in any part of the body, such as salivary gland, submandibular gland, trachea, lung, breast, skin and lacrimal gland. Results: The ribosomal protein L39-L transcription level was 6.5-fold higher in the drug-resistant human lacrimal gland adenoid cystic carcinoma cell line than in the susceptible cell line by quantitative RT-PCR analysis. Conclusions: The ribosomal protein L39-L gene could possibly have influence on the drug resistance mechanism of lacrimal gland adenoid cystic carcinoma cells
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
